Filtered By:
Condition: Arrhythmia
Drug: Beta-Blockers
Procedure: Electrocardiogram
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19 results found since Jan 2013.
Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials
ConclusionIntravenous beta-blockers improved the MSI, decreased the risk of VT/VF in the first 24 h, and were associated with increased LVEF at 1 week and 6 months following PCI. In particular, intravenous beta-blockers started before PCI is beneficial for patients with LAD lesions.
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research
Case Report of High-Grade Atrioventricular Block and Takotsubo Cardiomyopathy
CONCLUSION: When AVB or other arrhythmias initiate a TTC, the patient can experience sudden cardiac death and decompensate quickly. Therefore, clinicians should understand this rare but fatal complication because these patients require pacemakers and beta blockers.PMID:35348088 | PMC:PMC8817916 | DOI:10.7812/TPP/21.006
Source: The Permanente journal - March 29, 2022 Category: General Medicine Authors: Rohan Prasad Mohammad Fahad Salam Shaurya Srivastava Fnu Samreen Zulfiqar Qutrio Baloch Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
